PreU7-53

Observational study of patients with DMD theoretically treatable with exon skipping 53

Hub Summary

PreU7-53 is an observational cohort study. This natural history study is designed to monitor upper limb muscle impairment in patients potentially treatable with AAV-mediated exon skipping.

Study Number: NCT01385917

Description by Genethon

PreU7-53 is a natural history study. The objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with Duchenne Muscular Dystrophy (DMD), potentially treatable with AAV-mediated exon 53 skipping.

 
Primary Outcome Measures

PreU7-53 is a natural history study [Time Frame: Every year]

The objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with DMD, potentially treatable with AAV-mediated exon 53 skipping.

 
Can I take part?

 
Inclusion Criteria

  • Diagnosis of Duchenne muscular dystrophy confirmed by at least genetic testing, theoretically treatable by exon 53 skipping.
  • Age between ≥ 12 and <20 years old.
  • Non ambulant patients (ie; inability to walk more than 10 meters without any of assistance).
  • Patients covered by a national health insurance scheme.
  • Signed informed consent.

 
Exclusion Criteria

  • Patient incapable of sitting upright in a wheelchair for at least one hour.
  • Patients with severe intellectual impairment preventing them from fully understanding the exercises to be performed.
  • Recent (less than 6 months ago) upper limb surgery or trauma. This criteria is however not definitive. Patients who have undergone upper limb surgery or trauma may nonetheless be enrolled once the 6 month period is over.
  • Known immune deficiency.
  • Contraindications to NMR exams
 
Download PDF
Trial Status
Ongoing (fully recruited)
UK Locations
Trial Sponsor
Genethon
Age
12-20
Mutation Specific
Mutation specific therapies, Amenable to treatments with Exon 53 skipping
Muscle Biopsy
No Muscle Biopsy Required
Phase
Observational
Length Of Participation
TBC
Recruitment Target
45
Ambulatory
Non-ambulant
Therapeutic Category
Natural History